Literature DB >> 29382075

Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.

Wenqing Cai1,2, Jingwei Wu3, Wei Liu4, Yafei Xie5, Yuqiang Liu6, Shuo Zhang7, Weiren Xu8, Lida Tang9, Jianwu Wang10, Guilong Zhao11.   

Abstract

In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a-1x and 1ha-1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200- and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.

Entities:  

Keywords:  URAT1 inhibitor; gout; hyperuricemia; lesinurad; structure-activity relationship (SAR); synthesis

Mesh:

Substances:

Year:  2018        PMID: 29382075      PMCID: PMC6017028          DOI: 10.3390/molecules23020252

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  40 in total

Review 1.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

2.  Modulating reactivity and diverting selectivity in palladium-catalyzed heteroaromatic direct arylation through the use of a chloride activating/blocking group.

Authors:  Benoît Liégault; Ivan Petrov; Serge I Gorelsky; Keith Fagnou
Journal:  J Org Chem       Date:  2010-02-19       Impact factor: 4.354

Review 3.  Lesinurad: First Global Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

4.  Multisubstrate inhibitors of dopamine beta-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione.

Authors:  L I Kruse; C Kaiser; W E DeWolf; J S Frazee; E Garvey; E L Hilbert; W A Faulkner; K E Flaim; J L Sawyer; B A Berkowitz
Journal:  J Med Chem       Date:  1986-12       Impact factor: 7.446

5.  Identification, synthesis, and enzymology of non-natural glucosinolate chemopreventive candidates.

Authors:  Jared R Mays; Rachel L Weller Roska; Sami Sarfaraz; Hasan Mukhtar; Scott R Rajski
Journal:  Chembiochem       Date:  2008-03-25       Impact factor: 3.164

Review 6.  A concise history of gout and hyperuricemia and their treatment.

Authors:  George Nuki; Peter A Simkin
Journal:  Arthritis Res Ther       Date:  2006-04-12       Impact factor: 5.156

7.  Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.

Authors:  Philip K Tan; Jennifer E Farrar; Eric A Gaucher; Jeffrey N Miner
Journal:  Mol Biol Evol       Date:  2016-06-26       Impact factor: 16.240

8.  Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.

Authors:  Fredrik Nyberg; Laura Horne; Robert Morlock; Javier Nuevo; Chris Storgard; Lalitha Aiyer; Dionne M Hines; Xavier Ansolabehere; Pierre Chevalier
Journal:  Adv Ther       Date:  2016-05-26       Impact factor: 3.845

9.  Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Authors:  Jeffrey N Miner; Philip K Tan; David Hyndman; Sha Liu; Cory Iverson; Payal Nanavati; David T Hagerty; Kimberly Manhard; Zancong Shen; Jean-Luc Girardet; Li-Tain Yeh; Robert Terkeltaub; Barry Quart
Journal:  Arthritis Res Ther       Date:  2016-10-03       Impact factor: 5.156

Review 10.  Uric acid nephrolithiasis.

Authors:  Scott E Liebman; Jeremy G Taylor; David A Bushinsky
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

View more
  3 in total

1.  Two- and three-dimensional QSAR studies on hURAT1 inhibitors with flexible linkers: topomer CoMFA and HQSAR.

Authors:  Tingting Zhao; Zean Zhao; Fengting Lu; Shan Chang; Jiajie Zhang; Jianxin Pang; Yuanxin Tian
Journal:  Mol Divers       Date:  2019-03-13       Impact factor: 2.943

2.  Effect of Eurycoma longifolia Stem Extract on Uric Acid Excretion in Hyperuricemia Mice.

Authors:  Ruixia Bao; Mengyang Liu; Dan Wang; Shaoshi Wen; Haiyang Yu; Yi Zhong; Zheng Li; Yi Zhang; Tao Wang
Journal:  Front Pharmacol       Date:  2019-12-10       Impact factor: 5.810

3.  Effects of Osthol Isolated from Cnidium monnieri Fruit on Urate Transporter 1.

Authors:  Yuusuke Tashiro; Ryo Sakai; Tomoko Hirose-Sugiura; Yukio Kato; Hirotaka Matsuo; Tappei Takada; Hiroshi Suzuki; Toshiaki Makino
Journal:  Molecules       Date:  2018-11-01       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.